Search results

Frequently asked questions on the Mo-99 Manufacturing Facility and the ANSTO Nuclear Medicine project.

ANSTO manufacture and supply a range of radiopharmaceuticals, radiochemicals, kits and accessories for use in research, industry and the health sector.

Consortium will map the 86 billion nerve cells, 100 trillion connections and neurotransmitters in the human brain.

Using PET and simulations to verify the accuracy of dose and range in advanced therapy with heavy ions

$80.2 million in new funding to expand the research capabilities of the Australian Synchrotron.

Researchers from the Health Research and Technology Group at ANSTO and the University of Wollongong have developed a new device that could improve the quality control of accelerator-based boron neutron capture therapy, a promising radiation therapy for treating aggressive cancers. 

The new facility will be built around a product line of ANSTO’s design – a new Technetium-99m generator – that will enable greater process automation than is possible with existing technology, leading to improvements in efficiency, quality and importantly the highest levels of production safety.

The International Synchrotron Access Program (ISAP) is administered by the Australian Synchrotron and is designed to assist Australian-based synchrotron users to access overseas synchrotron related facilities.

This program explores the mechanism and outcome of the interaction of radiation on biological systems in order to improve our understanding of the impact of radiation on the brain, optimise radiotherapy and develop mitigation strategies for space travellers.

A world-class national research facility that uses accelerator technology to produce a powerful source of light-X rays and infrared radiation a million times brighter than the sun.

Researchers based at Monash University and the Swedish Museum of Natural History have pioneered the use of nuclear imaging techniques at ANSTO’s Centre for Neutron Scattering to resolve long-standing problems in plant evolutionary history linked to wildfires.

ANSTO’s Australian Synchrotron has been working on an initiative that could substantially improve radiotherapy treatment for cancer patients. 

A targeted radioactive infusion that is a game-changer in late-stage prostate cancer can also dramatically improve outcomes for patients in earlier stages of this disease, a Peter Mac-led study has shown.

ANSTO’s Dr Joanne Lackenby and Dr Katie Sizeland have been selected 2018 Superstars of STEM as some of Australia’s most inspiring scientists, technologists and educators.